Biotech Co.*
(Country;
Symbol)		 Pharma Co.
(Country)		 Product Terms/Details (Date)
Clinical Data
Inc. (CLDA)		 Merck KGaA (Germany) Clinical Data exercised its right to manufacture vilazodone The original deal with Clinical Data subsidiary Genaissance Pharmaceuticals Inc. was signed in 2004; Merck gets about $1.6M in Clinical Data stock (8/17)
Giaconda
Ltd. (Australia;
ASX:GIA)		 Orphan Australia Pty. Ltd. (Australia) Orphan intends to license Giaconda's Crohn's disease product Myoconda The deal would give Orphan exclusive rights in Australia, South Africa, Namibia and Asia; terms would be worked out later (8/1)
Calando
Pharmaceuticals
Inc. (majority
owned by
Arrowhead
Research Corp.)		 Agilent Technologies Inc. Agilent will manufacture the active siRNA component in Calando's RNAi product CALAA01 The siRNA anticancer agent is in preclinical development; terms of the deal were not disclosed (7/26)
Lipoxen plc
(UK: AIM:LPX)		 Serum Institute of India Ltd. (India) SIIL will develop technology for the manufacture of polysialic acid and its derivatives for Lipoxen The technology will be used in the development of PolyXen, a natural biopolymer for pegylation of protein drugs (8/3)
Lpath Inc.
(OTC BB:LPTN)		 Laureate Pharma Inc. Laureate will provide manufacturing and related services for Lpath's Sphingomab The preclinical candidate is a humanized monoclonal antibody specific for sphingo- sine-1-phosphate; terms of the deal were not disclosed (8/22)
Valera
Pharmaceuticals
Inc.*		 Spepharm Holding BV (the Netherlands) Spepharm got exclusive rights to market Vantas and Supprelin-LA in the European Union, Switzerland and Norway Valera will own 19.9% of Spepharm, and will get royalties of 40% on sales of the implant products, for treating prostate cancer and central precocious puberty, respectively (7/20)
Notes:
# The information in the chart does not cover agricultural agreements or those between biotech companies.
* Private companies are indicated with an asterisk.
Unless otherwise noted, stock symbols listed are on the Nasdaq market.
AIM = Alternative Investment Market; ASX = Australian Stock Exchange; OTC BB = Over-the-Counter Bulletin Board.